{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:07:40Z","timestamp":1780621660189,"version":"3.54.1"},"reference-count":38,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T00:00:00Z","timestamp":1651968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Isra University, Amman, Jordan","award":["# 2019\/2018\/17\u2013174"],"award-info":[{"award-number":["# 2019\/2018\/17\u2013174"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>2-(4-Chlorophenyl)-5-benzoxazoleacetic acid (CBA) and its ester, methyl-2-(4-chloro-phenyl)-5-benzoxazoleacetate (MCBA), were synthesized, and their structures were confirmed by 1HNMR, IR, and mass spectrophotometry. The anti-psoriatic activities of CBA and MCBA were tested using an imiquimod (IMQ)-induced psoriatic mouse model, in which mice were treated both topically (1% w\/w) and orally (125 mg\/kg) for 14 days. The erythema intensity, thickness, and desquamation of psoriasis were scored by calculating the psoriasis area severity index (PASI). The study also included the determination of histopathological alterations in the skin tissues of treated mice. Topical and oral administration of CBA and MCBA led to a reduction in erythema intensity, thickness, and desquamation, which was demonstrated by a significant decrease in the PASI value. In addition, skin tissues of mice treated with CBA and MCBA showed less evidence of psoriatic alterations, such as hyperkeratosis, parakeratosis, scale crust, edema, psoriasiform, and hyperplasia. After administration of either topical or oral dosing, the anti-psoriatic effects were found to be stronger in MCBA-treated than in CBA-treated mice. These effects were comparable to those produced by Clobetasol propionate, the reference drug. This drug discovery could be translated into a potential new drug for future clinical use in psoriasis treatment.<\/jats:p>","DOI":"10.3390\/molecules27093023","type":"journal-article","created":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T21:31:20Z","timestamp":1652045480000},"page":"3023","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Synthesis and In-Vivo Evaluation of Benzoxazole Derivatives as Promising Anti-Psoriatic Drugs for Clinical Use"],"prefix":"10.3390","volume":"27","author":[{"given":"Rami","family":"Ayoub","sequence":"first","affiliation":[{"name":"Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman 11622, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Jilani","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qais","family":"Jarrar","sequence":"additional","affiliation":[{"name":"Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman 11622, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raad","family":"Alani","sequence":"additional","affiliation":[{"name":"Department of Physiotherapy, Faculty of Allied Medical Sciences, Isra University, Amman 11622, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-7900","authenticated-orcid":false,"given":"Chrismawan","family":"Ardianto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khang Wen","family":"Goh","sequence":"additional","affiliation":[{"name":"Faculty of Data Science and Information Technology, INTI International University, Nilai 71800, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9680-0026","authenticated-orcid":false,"given":"Dalia","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Physiotherapy, Faculty of Allied Medical Sciences, Isra University, Amman 11622, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4840-0460","authenticated-orcid":false,"given":"Said","family":"Moshawih","sequence":"additional","affiliation":[{"name":"PAP Rashidah Sa\u2019adatul Bolkiah Institute of Health Sciences, Universiti Brunei Darussalam, Gadong BE1410, Brunei"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/ijd.14864","article-title":"Global burden of psoriasis\u2013comparison of regional and global epidemiology, 1990 to 2017","volume":"59","author":"AlQassimi","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1172\/JCI200422147","article-title":"Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities","volume":"113","author":"Nickoloff","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","article-title":"Medical progress on psoriasis","volume":"352","author":"Michael","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2133.2006.07405.x","article-title":"Europso Patient EUROPSO Patient Survey Group European patient perspectives on the impact of psoriasis: The EUROPSO patient membership survey","volume":"155","author":"Dubertret","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/jid.2013.404","article-title":"IL-6 Regulates Neutrophil Microabscess Formation in IL-17A-Driven Psoriasiform Lesions","volume":"134","author":"Croxford","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"E3422","DOI":"10.1073\/pnas.1400513111","article-title":"IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms","volume":"111","author":"Ha","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of Psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","article-title":"T cell subsets and their signature cytokines in autoimmune and inflammatory diseases","volume":"74","author":"Raphael","year":"2015","journal-title":"Cytokine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2310\/7750.2012.11124","article-title":"Phototherapy in psoriasis: A review of mechanisms of action","volume":"17","author":"Wong","year":"2013","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ad.2014.09.004","article-title":"Etanercept in the treatment of psoriatic arthritis","volume":"106","author":"Puig","year":"2015","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2017.07.047","article-title":"Serious infections among a large cohort of subjects with systemically treated psoriasis","volume":"77","author":"Dobry","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1517\/13543784.17.11.1685","article-title":"FLT3 inhibitors for the treatment of autoimmune disease","volume":"17","author":"Whartenby","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1111\/ajt.13309","article-title":"Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation","volume":"15","author":"Sikma","year":"2015","journal-title":"Am. J. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/S0968-0896(02)00327-9","article-title":"Synthesis and evaluation of anticancer benzoxazoles and benzimidazoles related to UK-1","volume":"10","author":"Kumar","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"ref_16","first-page":"717","article-title":"Synthesis, characterization and biological evaluation of some 2-arylbenzoxazole acetic acid derivatives as promising anticancer agents","volume":"77","author":"Abualassal","year":"2020","journal-title":"Acta Pol. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuroscience.2016.02.049","article-title":"A novel 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanal oxime compound is a potent Transient Receptor Potential Ankyrin 1 and Vanilloid 1 (TRPA1 and V1) receptor antagonist","volume":"324","author":"Payrits","year":"2016","journal-title":"Neuroscience"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2014.02.050","article-title":"Synthesis, antimicrobial and cytotoxic activities of pyrimidinyl benzoxazole, benzothiazole and benzimidazole","volume":"77","author":"Seenaiah","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejphar.2013.12.039","article-title":"Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl) piperazin-1-yl) butyl) benzo [d] oxazol-2 (3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine in vitro","volume":"724","author":"Kaushal","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2147\/DDDT.S48636","article-title":"Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis","volume":"7","author":"Jilani","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9193","DOI":"10.1002\/jcb.28195","article-title":"A benzoxazole derivative PO-296 inhibits T lymphocyte proliferation by the JAK3\/STAT5 signal pathway","volume":"120","author":"Luo","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/archderm.1983.01650310010002","article-title":"Benoxaprofen improves psoriasis. A double-blind study","volume":"119","author":"Kragballe","year":"1983","journal-title":"Arch. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jhet.5570090332","article-title":"The synthesis of benzoxazole-5-acetic acid derivatives","volume":"9","author":"Wright","year":"1972","journal-title":"J. Heterocycl. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/00397918508076845","article-title":"A Facile Synthesis of (\u00b1) 2-(4-Chlorophenyl)-\u03b1-Methyl-5-Benzoxazoleacetic Acid (Benoxaprofen)","volume":"15","year":"1985","journal-title":"Synth. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1021\/jm00235a012","article-title":"2-Aryl-5-benzoxazolealkanoic acid derivatives with notable antiinflammatory activity","volume":"18","author":"Dunwell","year":"1975","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1600-0625.2007.00629.x","article-title":"Immunopathogenesis of psoriasis","volume":"16","author":"Sabat","year":"2007","journal-title":"Exp. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2133.1999.02963.x","article-title":"Clinical measures of disease severity and outcome in psoriasis: A critical appraisal of their quality","volume":"141","author":"Po","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"ref_28","first-page":"443","article-title":"Histopathology and histochemistry of psoriasis. II. Dynamics of lesions during treatment","volume":"84","author":"Gordon","year":"1967","journal-title":"Arch. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"Mourits","year":"2009","journal-title":"J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0190-9622(99)70406-8","article-title":"Duration of remission of psoriasis therapies","volume":"41","author":"Koo","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0733-8635(18)30955-0","article-title":"The Use of Topical Steroids in Psoriasis","volume":"2","author":"Cornell","year":"1984","journal-title":"Dermatol. Clin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.otc.2010.04.003","article-title":"A Comprehensive Review of the Adverse Effects of Systemic Corticosteroids","volume":"43","author":"Poetker","year":"2010","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1016\/j.tetlet.2013.09.092","article-title":"Nano ceria catalyzed synthesis of substituted benzimidazole, benzothiazole, and benzoxazole in aqueous media","volume":"54","author":"Shelkar","year":"2013","journal-title":"Tetrahedron Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: Design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0163-7258(81)90009-7","article-title":"Prodrug design","volume":"14","author":"Notari","year":"1981","journal-title":"Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cbpa.2009.04.620","article-title":"Prodrugs: Bridging pharmacodynamic\/pharmacokinetic gaps","volume":"13","author":"Testa","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_37","unstructured":"National Research Council (2010). Guide for the Care and Use of Laboratory Animals."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Pang, X., Zhang, K., Huang, J., Wang, H., Gao, L., Wang, T., Sun, Y., Chen, L., and Wang, J. (2018). Decryption of Active Constituents and Action Mechanism of the Traditional Uighur Prescription (BXXTR) Alleviating IMQ-Induced Psoriasis-Like Skin Inflammation in BALB\/c Mice. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19071822"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/9\/3023\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:07:53Z","timestamp":1760137673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/9\/3023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,8]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["molecules27093023"],"URL":"https:\/\/doi.org\/10.3390\/molecules27093023","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,8]]}}}